Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Antengene Announces Commercial Availability of XPOVIO® (Selinexor), for the Treatment of Relapsed/Refractory Multiple Myeloma, Prescribed for the First Time Across Mainland China 2022-05-16 11:20
Antengene to Participate in Three Upcoming Investor Conferences in May/June 2022-05-06 08:30
Antengene Announces Latest Clinical Trial Data of ATG-008 (onatasertib) to be presented in the upcoming 2022 American Society of Clinical Oncology Annual Meeting 2022-04-29 22:30
Antengene Announces Submission to the Human Research Ethics Committee in Australia for a Phase I Trial of ATG-018 2022-04-27 08:30
Antengene Announces Publication of Five Posters at the 2022 American Association for Cancer Research (AACR) Annual Meeting 2022-04-11 08:30
Antengene's Pivotal "MARCH" Study to Evaluate Selinexor (ATG-010) in Relapsed or Refractory Multiple Myeloma Published in BMC Medicine 2022-04-06 20:03
Antengene Announces IND Approval in China for a Phase II Study of Eltanexor (ATG-016) in Patients with High-Risk Myelodysplastic Syndromes 2022-03-30 09:00
Antengene Announces 2021 Full Year Financial Results and Provides Corporate Updates 2022-03-18 22:12
Antengene Announces IND Approval in China for the Phase I Study of ATG-101 (PD-L1/4-1BB Bispecific Antibody) for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma 2022-03-10 08:52
Antengene Announces Five Upcoming Presentations at the 2022 American Association for Cancer Research Annual Meeting 2022-03-09 20:00
Antengene Announces XPOVIO® Approved by the TGA in Australia for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Triple Class-Refractory Multiple Myeloma 2022-03-09 19:08
Antengene Announces XPOVIO® Regulatory Approval in Singapore for the Treatment of Relapsed and/or Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Three Indications 2022-03-02 08:47
Antengene Announces HREC Approval in Australia for the Phase I Trial of the Small Molecule CD73 Inhibitor ATG-037 2022-02-07 08:30
Antengene to Present at the 40th Annual J.P. Morgan Healthcare Conference 2022-01-05 12:50
Antengene Announces NDA Approval by NMPA for XPOVIO®, China's First XPO1 inhibitor, for the Treatment of Adults with Relapsed or Refractory Multiple Myeloma 2021-12-17 22:27
Antengene and XtalPi Announce AI-Driven R&D Collaboration 2021-12-16 16:30
1 2